文献速递血液净化与透析

药物涂层球囊治疗功能不良的血液透析动静脉内瘘:一项随机对照试验

Drug-Coated Balloon Angioplasty for Dysfunctional Arteriovenous Hemodialysis Fistulae: A Randomized Controlled Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2023-12-18

本研究为前瞻性多中心随机对照试验,纳入244例动静脉内瘘静脉狭窄≥50%且伴显著血流动力学改变症状的患者,预扩张成功后按1:1随机接受紫杉醇涂层球囊(AcoArt Orchid)或无涂层对照球囊。结果显示DCB组6个月和12个月靶病变一期通畅率均优于对照组,12个月内再次干预次数更少,安全性终点两组无差异。

要点

  • DCB组6个月靶病变一期通畅率91%,对照组67%,差异24.63%(95%CI 14.68–34.58,P<0.001)。
  • DCB组12个月靶病变一期通畅率66%,对照组46%(95%CI 6.57–32.08,P=0.004)。
  • DCB组12个月内人均再次干预次数0.39次,对照组0.77次(P=0.001),主要安全性终点无差异(P=0.25)。

核心结论

  • AcoArt Orchid药物涂层球囊治疗功能不良的血液透析动静脉内瘘狭窄病变,6个月和12个月一期通畅率均优于普通球囊血管成形术。
  • DCB组12个月内维持靶病变通畅所需的再次干预次数更少,且1年安全性相当。

研究设计与样本

  • AcoArt III/Arterio-venous Fistula in China(NCT03366727)为前瞻性、多中心、随机对照研究。
  • 纳入动静脉内瘘静脉狭窄≥50%且症状提示显著血流动力学改变的患者,预扩张成功(残余狭窄≤30%)后按1:1随机分组。
  • 共纳入244例患者,两组各122例。
  • 主要疗效终点于6个月评估,安全性于术后30天内评估,并分析12个月结果。

主要发现

  • 6个月靶病变一期通畅率DCB组91%(106/116),普通球囊组67%(79/118),差异24.63%(95%CI 14.68–34.58,P<0.001)。
  • 12个月靶病变一期通畅率DCB组66%(74/112),普通球囊组46%(52/112)(95%CI 6.57–32.08,P=0.004)。
  • 12个月内人均再次干预次数DCB组0.39次(48/122),普通球囊组0.77次(94/122)(P=0.001)。
  • 主要安全性终点两组无差异(P=0.25)。

关键数值与推荐

  • 纳入标准:动静脉内瘘静脉狭窄≥50%,且症状提示显著血流动力学改变。
  • 预扩张要求:高压球囊预扩张成功,残余狭窄≤30%后方可随机。
  • 主要疗效终点:6个月靶病变一期通畅率。
  • 次要疗效终点:12个月靶病变一期通畅率。
  • 安全性评估窗口:术后30天内。

临床怎么用

  • 对于功能不良的血液透析动静脉内瘘狭窄病变,在高压球囊预扩张成功后,可考虑使用紫杉醇涂层球囊(AcoArt Orchid)以减少再狭窄和再次干预。
  • DCB组6个月和12个月一期通畅率更高、12个月内再次干预次数更少,且1年安全性相当,支持其在该人群中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to evaluate the efficacy and safety of paclitaxel-coated balloons (AcoArt Orchid) in treating dysfunctional arteriovenous fistulae. METHODS: The drug-eluting balloon for arteriovenous (AV) fistula in China trial was a prospective, multicenter, randomized controlled study. Patients who had ≥50% venous stenosis of the AV fistula and symptoms indicating significant hemodynamic changes were included. After successful predilation with a high-pressure balloon (residual stenosis ≤30%), patients were randomized 1:1 to either a paclitaxel-coated balloon or an uncoated control balloon. The primary efficacy outcome was assessed at 6 months, and safety assessment was conducted within 30 days of the procedure. The 12-month results were also analyzed. RESULTS: The study included 244 patients, equally distributed between the two groups. The primary target lesion patency was 91% (106/116) for the drug-coated balloon (DCB) group and 67% (79/118) for the plain balloon catheter group, representing a difference of 24.63% (95% confidence interval, 14.68 to 34.58; P < 0.001). The secondary efficacy end point was primary target lesion patency at 12 months, which was 66% (74/112) for the DCB group and 46% (52/112) for the plain balloon catheter group (95% confidence interval, 6.57 to 32.08; P = 0.004). The mean number of reinterventions per patient to maintain target lesion patency during the 12 months after the index procedure was 0.39 (48/122) in the DCB group and 0.77 (94/122) in the plain balloon catheter group ( P = 0.001). The primary safety end point did not differ between groups ( P = 0.25). CONCLUSIONS: AcoArt Orchid DCB showed better primary patency rates compared with plain balloon angioplasty for treating stenotic lesions in dysfunctional hemodialysis AV fistulae at 6 and 12 months. It required fewer repeated interventions and had comparable safety in 1 year. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: AcoArt III/Arterio-venous Fistula in China, NCT03366727 .

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Wang P, Wang Y, et al. Drug-Coated Balloon Angioplasty for Dysfunctional Arteriovenous Hemodialysis Fistulae: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2023. PMID: 38191561. doi:10.2215/CJN.0000000000000359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。